Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC

September 12th 2022

Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.

Tislelizumab Provides Favorable Efficacy in Asian and Non-Asian Patients with Previously Treated Advanced NSCLC

September 12th 2022

Tislelizumab continued to demonstrate an improved clinical benefit compared with docetaxel in both Asian and non-Asian patients with previously treated advanced non–small cell lung cancer.

Updated ADAURA Data Reinforce Adjuvant Osimertinib as SOC for EGFR-Mutated, Stage IB-IIIA NSCLC

September 11th 2022

Adjuvant osimertinib resulted in a 77% reduction in the risk of disease recurrence or death in patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer, with a disease-free survival improvement observed irrespective of prior adjuvant chemotherapy or disease stage.

High-Dose MEDI5752 Induces Clinical Benefit in NSCLC at the Cost of Significant Toxicity

September 11th 2022

MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Tremelimumab Plus Durvalumab/Chemo Maintains OS Benefit in Metastatic NSCLC

September 11th 2022

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC

September 10th 2022

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

September 9th 2022

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

CEACAM5 Shows Great Potential as Therapeutic Target in NSCLC

September 7th 2022

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

September 2nd 2022

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Erlotinib Displays Long-Term DFS Benefit, Meaningful OS Improvement vs Chemotherapy in EGFR+ NSCLC

September 1st 2022

Erlotinib continued to elicit a disease-free survival and overall survival benefit vs vinorelbine/cisplatin chemotherapy in patients with EGFR-positive non–small cell lung cancer, according to updated OS data and an exploratory analysis from the phase 2 EVAN trial.

Vopratelimab Plus Pimivalimab Fails to Meet Tumor Reduction End Point in Select Metastatic NSCLC

August 31st 2022

The addition of vopratelimab to pimivalimab did not elicit a significant mean percent change of baseline tumor size in all measurable lesions vs pimivalimab alone in patients with immunotherapy-naïve, metastatic non–small cell lung cancer who were positive for the TISvopra predictive biomarker.

Sotorasib Meets PFS End Point in Previously Treated, KRAS G12C–Mutated NSCLC

August 31st 2022

Sotorasib demonstrated superiority and a statistically significant benefit in progression-free survival vs standard-of-care docetaxel in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.

Frontline Gefitinib Plus Chemotherapy Improves PFS2 Vs Gefitinib Alone in EGFR-Mutated NSCLC

August 30th 2022

The combination of gefitinib plus chemotherapy generated a benefit in time to second progression vs gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer.

Adjuvant Osimertinib Gets Japanese Approval for Early-Stage, EGFR-Mutated NSCLC

August 26th 2022

The Japanese Ministry of Health, Labour, and Welfare has approved osimertinib for use as an adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer.

FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 25th 2022

Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.

European Union Green Lights PD-L1 Companion Diagnostic for Adjuvant Atezolizumab in NSCLC

August 24th 2022

CE label expansion was granted to the Ventana PD-L1 assay for use as a companion diagnostic to identify patients with non–small cell lung cancer who are eligible for treatment with adjuvant atezolizumab.

Abivertinib Demonstrates Response and Survival Benefits in Pretreated EGFR T790M–Mutant NSCLC

August 23rd 2022

The novel third-generation EGFR inhibitor abivertinib generated a positive overall response rate and overall survival in heavily pretreated Chinese patients with EGFR T790M–mutated non–small cell lung cancer who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial (NCT02330367).

Bevacizumab Biosimilar CT-P16 Approved in Europe for Multiple Cancer Types

August 19th 2022

The European Commission has approved the bevacizumab biosimilar, CT-P16, for the treatment of patients with metastatic breast cancer, non–small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer, and cervical cancer.

Dr. Levy on the Approval of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.